Buy Sanofi India; target of Rs 9249: Sharekhan

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9249 in its research report dated October 27, 2020.

Buy Sanofi India; target of Rs 9820: ICICI Direct

ICICI Direct is bullish on Sanofi India recommended buy rating on the stock with a target price of Rs 9820 in its research report dated October 28, 2020.

Sanofi India Standalone September 2020 Net Sales at Rs 686.60 crore, down 11.87% Y-o-Y

Sanofi India September-quarter net profit at Rs 133 crore

The company had posted a net profit of Rs 126.6 crore in the corresponding period of the previous fiscal, Sanofi India said in a filing to BSE.

Sanofi India Standalone September 2020 Net Sales at Rs 686.60 crore, down 11.87% Y-o-Y

Buy Sanofi India; target of Rs 8815: ICICI Direct

ICICI Direct is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 8815 in its research report dated July 29, 2020.

Sanofi India Standalone June 2020 Net Sales at Rs 710.50 crore, down 5% Y-o-Y

Sanofi India Q2 net profit at Rs 136.3 crore

The company had posted a net profit of Rs 97.4 crore for the corresponding period of the previous fiscal, Sanofi India said in a BSE filing.

Sanofi India Q1 net profit declines 8% to Rs 85.4 crore

Revenue from operations of the company stood at Rs 784.5 crore for the quarter under consideration. It was Rs 717.3 crore for the same period a year ago, it added.

Sanofi India shares hit all-time high on Q4 numbers; French arm actively pursuing antidote to coronavirus

The company's profit for the period jumped 22.7 percent year-on-year (YoY), coming at Rs 97.3 crore in Q4CY19 against Rs 79.3 crore in Q4CY18.

Sanofi India Standalone June 2019 Net Sales at Rs 747.90 crore, up 9.41% Y-o-Y

Buy Sanofi India; target of Rs 6930: Motilal Oswal

Motilal Oswal is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 6930 in its research report dated May 07, 2019.

Sanofi India Q1 net profit up 13% to Rs 93 cr

The company had posted a net profit of Rs 82.5 crore for the corresponding period of the previous fiscal, Sanofi India said in a filing to the BSE.

Sanofi India Standalone March 2019 Net Sales at Rs 717.30 crore, up 16.12% Y-o-Y

Sanofi India Standalone September 2018 Net Sales at Rs 743.80 crore, up 11.43% Q-o-Q

Sanofi India net profit rises 2.49% to Rs 119 cr in Jul-Sep quarter

The company had posted a net profit of Rs 116.3 crore for the corresponding period of the previous fiscal, Sanofi India said in a filing to BSE.

Sanofi India Standalone September 2018 Net Sales at Rs 743.80 crore, up 11.43% Q-o-Q

Sanofi launches its multiple sclerosis treatment drug in India

The drug offers patients diagnosed with multiple sclerosis the efficacy and convenience of once-a-day oral treatment.

Buy Sanofi India, target Rs 5335: Abhishek Mondal

Traders can buy the stock around in dips around Rs 5,040-5,050 with a stop loss below Rs 4,880 (closing) for the target of Rs 5,335.

Sanofi India March quarter net up 37% at Rs 82 cr

The company had posted a net profit of Rs 60.1 crore in January-March period of 2016-17, Sanofi India said in a filing to BSE.

Buy Sanofi India; target of Rs 6000: Dolat Capital

Dolat Capital is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 6000 in its research report dated April 13, 2018.

Hold Sanofi India; target of Rs 5160: Centrum

Centrum Research has recommended hold rating on Sanofi India with a target price of Rs 5160 in its research report dated February 23, 2018.

Sanofi India Q4 net jumps 44% to Rs 76 crore

The company had posted a profit of Rs 52.6 crore for the corresponding period of the previous fiscal.

Buy Sanofi India; target of Rs 5000: Motilal Oswal

Motilal Oswal is bullish on Sanofi India has recommended Buy rating on the stock with a target price of Rs 5000 in its research report dated October 31, 2017.

Buy Sanofi India; target of Rs 4900: Centrum

Centrum is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated November 01, 2017.